Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.80.

A number of brokerages have issued reports on RGLS. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $1,403,000. NEA Management Company LLC purchased a new position in Regulus Therapeutics in the third quarter worth approximately $10,154,000. Barclays PLC lifted its stake in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares during the last quarter. State Street Corp grew its holdings in Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after acquiring an additional 33,496 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Regulus Therapeutics by 10.4% in the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after purchasing an additional 37,480 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Trading Down 5.8 %

Shares of NASDAQ:RGLS opened at $1.23 on Friday. The company has a market capitalization of $80.24 million, a price-to-earnings ratio of -1.14 and a beta of 1.60. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79. The business has a 50-day moving average price of $1.53 and a 200 day moving average price of $1.59.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, equities research analysts predict that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.